Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 Updated Seasonal Influenza Vaccine Study
NCT07884175Phase 4Not yet recruiting
- Sponsor
- Moderna Inc
- Start
- Oct 2026
- Primary completion
- Dec 2026
01
Overview
Phase 4, randomised trial of mRNA-1010 in seasonal influenza (2 arms), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Titer of Anti-Hemagglutinin (HA) Antibodies at Day 29, Number of Participants Reaching Seroconversion at Day 29 and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mRNA-1010
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT07884175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884175.